International Isotopes raises $19.5 million:
This article was originally published in Clinica
Executive Summary
International Isotopes has closed a two-stage private equity financing, raising $19.5 million. The company says that the proceeds, together with an expected increase in product revenues over the next six months, should provide it with a positive cash flow by the end of the year. International Isotopes, of Denton, Texas, has just begun commercial production of Iodine-125 brachytherapy seeds, used for the treatment of prostate cancer. The product is in clinical development for treating tumours in the breast, eye and oesophagus. The company plans to begin commercial shipments of six radioisotopes and radiochemicals during the third and fourth quarter.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.